Story

Latigo Biotherapeutics Prices $345.6 Million IPO at $18 Per Share

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Latigo Biotherapeutics Prices $345.6 Million IPO at $18 Per Share
Text size
Background

Latigo Biotherapeutics, Inc., a clinical-stage company developing non-opioid pain medications, has priced its initial public offering of 19.2 million shares at $18.00 per share. The offering is expected to generate gross proceeds of approximately $345.6 million before underwriting discounts and commissions, according to a company press release dated August 6, 2026.

Offering Details

The IPO provides investors with a new opportunity in the biopharmaceutical sector, with shares scheduled to begin trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol LTGO. The offering is expected to close on August 10, 2026, subject to customary closing conditions.

Key details of the public offering include:

  • Shares Offered: 19,200,000 shares of common stock.
  • Price Per Share: $18.00.
  • Gross Proceeds: Approximately $345.6 million.
  • Underwriter Option: Underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the IPO price.
Sample IUX Markets – In-articleAd

Strategic Focus and Market Context

Latigo Biotherapeutics is focused on addressing the need for non-opioid pain medicines. The company's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor being developed for the treatment of acute pain. The capital raised from the IPO is expected to fund further clinical development of its pipeline.

The U.S. Securities and Exchange Commission (SEC) declared the company's registration statement effective on August 6, 2026. The offering is being managed by a syndicate of joint book-running managers that includes Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, and Guggenheim Securities, indicating strong institutional interest.

Read next

More on Stocks
Back to latest news

LATEST